Hepatitis C - Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

PHILADELPHIA – The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

“Chronic hepatitis C treatment is no longer challenging in the era of DAAs with an SVR of up to 97%. However, triple infection treatment with HCV, HIV and hepatitis B has not been explored in real life situations,” Nimy John, MD, from the University of Massachusetts Medical School, said during her presentation.

Read the article: 
https://www.healio.com/gastroenterology/hepatitis-c/news/online/%7B48f981a3-e83f-4e70-8c39-4acd467af6f7%7D/vosevi-safe-effective-in-triple-infected-patients-with-hcv-hbv-hiv

Healio Coverage:

American College of Gastroenterology Annual Meeting 
October 5, 2018 - October 10, 2018
See more from American College of Gastroenterology Annual Meeting